Oncimmune Net Receivables from 2010 to 2025

ONC Stock   1.14  0.23  16.79%   
Oncimmune Holdings' Net Receivables is increasing over the years with stable fluctuation. Net Receivables is expected to dwindle to about 339.8 K. During the period from 2010 to 2025 Oncimmune Holdings Net Receivables annual values regression line had geometric mean of  689,113 and mean square error of 2.8 T. View All Fundamentals
 
Net Receivables  
First Reported
2016-05-31
Previous Quarter
M
Current Value
311 K
Quarterly Volatility
2.6 M
 
Covid
Check Oncimmune Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncimmune Holdings' main balance sheet or income statement drivers, such as Depreciation And Amortization of 324.7 K, Interest Expense of 656.3 K or Selling General Administrative of 1.9 M, as well as many indicators such as . Oncimmune financial statements analysis is a perfect complement when working with Oncimmune Holdings Valuation or Volatility modules.
  
This module can also supplement various Oncimmune Holdings Technical models . Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Oncimmune Stock

Oncimmune Holdings financial ratios help investors to determine whether Oncimmune Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncimmune with respect to the benefits of owning Oncimmune Holdings security.